TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03163550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHN-789
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHN-789
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHN-789
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose
Study: NCT03513302

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 x 70 mL concentrated beet root juice depleted of nitrate per day for 14 days.
Study: NCT04035564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium < 1mEq/kg/day
Description: Sodium administration enteral and/or parenteral less than 1mEq/kg/day started on day of life 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium 5mEq/kg/day
Description: Sodium administration enteral and/or parenteral 5mEq/kg/day started on day of life 1
Study: NCT01357954

Intervention type: OTHER
Group type: OTHER
Intervention: Regular physiotherapy
Description: The child's regular physiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted Training
Description: Targeted training, 5 days a week for 6 months, up to 30 minutes a day
Study: NCT03571672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEFINITY
Description: All subjects will receive a single dose of DEFINITY®
Study: NCT02144831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
Description: comparisson of what is the efficacy and safety of 10 days to 30 day treatment of aspirin (ASA)+Clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
Description: comparisson of what is the efficacy and safety of 10 days to 30 day treatment of aspirin (ASA)+Clopidogrel
Study: NCT03036436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: A physical activity intervention, delivered remotely using a combination of the Fitbit application and support from a chartered physiotherapist.
Study: NCT03093636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)+Decision Support System (DSS)
Description: Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App and a study CGM at home for 12 weeks. The DSS contains a smart bolus advisor that adjusts the size of the correction insulin boluses based on short-term blood glucose predictions. It is able to complete this function by evaluating CGM values, insulin usage and carbohydrate intake record. It also contains an exercise advisor, a bedtime advisor, hypoglycemia risk and long-term tracker of HbA1c. Subjects will use study basal and bolus insulin during the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Glucose Monitor (CGM) alone
Description: Continuous Glucose Monitor (CGM) alone study participants will use a study CGM at home for 12 weeks. Subjects will use study basal and bolus insulin during the study.
Study: NCT03041142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary intervention
Description: Physical Activity, nutrition and Psychological

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine
Description: The participants continued to maintain their routine
Study: NCT00724412

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane
Description: Dry Eye relief eye drops

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optive
Description: Dry Eye relief eye drops
Study: NCT03141463

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vvax001 therapeutic cancer vaccine
Description: Vvax001 is a vaccine consisting of a replication-incompetent Semliki Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three consecutive doses, with an interval of 3 weeks.
Study: NCT03333148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nestle IMPACT Immunonutrition
Description: Along with standard of care nutritional therapy patients (n=146) will be asked to consume 3 cartons/day for 14 days of Nestle IMPACT Advanced Recovery Immunonutrition.

Intervention type: OTHER
Group type: OTHER
Intervention: Arm B- Standard of Care
Description: No intervention standard of care nutrition (n=146).
Study: NCT04403243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.5mg twice a day per os during the first three days and then 0.5mg daily per os if weight \< 86 kg or 0.5mg twice a day per os if weight \> 85kg for seven days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 5 MG
Description: Ruxolitinib - 5mg twice a day per os for ten days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]
Description: Secukinumab - 300mg subcutaneously singly

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy
Description: standard therapy for COVID 19
Study: NCT03873961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity laser therapy
Description: tissue photobiostimulation for pain reduction and healing enhancement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-level Laser therapy
Description: tissue photobiostimulation for pain reduction and healing enhancement.
Study: NCT02441348

Intervention type: BEHAVIORAL
Intervention: Conversation Training Therapy
Description: Conversational speech as the primary focus of voice therapy in individuals with muscle tension dysphonia or vocal fold lesions.
Study: NCT01538940

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal vaccine
Description: 15ug

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal vaccine
Description: 15ug

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Intradermal vaccine
Description: 15ug

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular vaccine
Description: 15ug

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular vaccine
Description: 15ug

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Intramuscular vaccine
Description: 15ug
Study: NCT00504140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m\^2 Intravenous Daily for 5 days, beginning one hour after IFN-alpha treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alpha
Description: 5x10\^6 mu/m\^2 Subcutaneously Daily for 5 Days
Study: NCT03694873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride
Description: one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.
Study: NCT01871155

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutri-jelly
Description: an edible nutritious gel for chewing and swallowing difficulties 1 box contains 250 ml with 250 kcal~1 serving is considered as food supplement
Study: NCT03689075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envarsus Oral Product
Description: Patients will be randomised to receive either envarsus or to continue on an immediate release tacrolimus formulation
Study: NCT00902148

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polylactic Acid Sheet
Description: SurgiWrapTM bioresorbable sheet will be secured directly below the abdominal incision.
Study: NCT02606266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension) at a dose of 16 mg/kg 2 times/day (max 900 mg/d) for 6 weeks.
Study: NCT00290875

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Use of Xrays for diagnosis
Study: NCT02017145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloraprep
Study: NCT01727011

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IPAS
Study: NCT01646619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: 10% MgSo4 (100mg/ml) given in a dose of 250mg/kg IV q 24 hrly for 3 doses(2.5ml/kg).~Diluent: Dextrose 5%.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline 0.9% Sodium Chloride is diluted in 5% Dextrose to be given as 2.5ml/kg IV q24 hrly for 3 doses.
Study: NCT02046070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets
Study: NCT03518268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vivomixx
Description: The intervention consists of 2 sachets a day containing the probiotic Vivomixx, for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention consists of 2 sachets a day of placebo, for 6 months
Study: NCT00371969

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Motivational Interview
Description: The intervention consists of a brief motivational interview, which is combined with daily alcohol monitoring through the use of an interactive voice response system IVR (automated telephone system).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Motivational Interview or viewing DVD
Description: Brief motivational interview, viewing a DVD on HIV self-care.
Study: NCT00219882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standardized turmeric root extract
Description: 1.5 gm of standardized tumeric root extract three times per day for seven consecutive days, followed by 3 gm of standardized tumeric root extract three times per day for seven consecutive days
Study: NCT02156557

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Colon KCC Heptapeptide
Description: * Your colonoscopy will happen as it would normally, including the medications, the colonoscope, and any clinically indicated biopsies or polypectomies.~* The fluorescent peptide will be sprayed on to the walls of your colon around the areas that might have a polyp, areas of IBD, or another area of interest. Your doctor will select one area to apply the peptide in your colon. The peptide comes in a single-use sealed vial from the investigational pharmacy. Sterile saline (salt-water) is added to the vial. The powder is mixed well and pulled into a syringe. The peptide is then injected into a special, single-use sprayer, like a garden hose, that fits down the endoscope channel. The peptide will be sprayed in your colon. This is part of the study.~* The endoscopist will take pictures of the area before and after the peptide spraying. They will use the camera that is part of the colonoscope.~* We will obtain copies of your endoscopy report and any pathology reports.
Study: NCT03554772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 (Celecoxib Oral Solution) 62.5 mg
Description: Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 (Celecoxib Oral Solution) 125 mg
Description: Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 (Celecoxib Oral Solution) 250 mg
Description: Oral Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Solution
Study: NCT01998893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse
Study: NCT03761394

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Testing Devices
Description: Pulsewatch system testing application on smartphone with smartwatch.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Testing Devices
Description: Pulsewatch system testing application on smartphone with smartwatch.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardea Solo by Cardiac Insight
Description: Gold-standard cardiac monitor for comparison of testing devices.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardea Solo by Cardiac Insight
Description: Gold-standard cardiac monitor for comparison of testing devices.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kardia Mobile by AliveCor
Description: Mobile ECG device for comparison of testing devices during the extended use period.
Study: NCT03856008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises focused on flexor muscles
Description: Exercises emphasis flexor muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises focused on extensor muscles
Description: Exercises emphasis extensor muscles.
Study: NCT03275688

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath Analysis
Description: Breath will be analyzed in all three groups using gas chromatography mass spectrometry.

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath Analysis
Description: Breath will be analyzed in all three groups using gas chromatography mass spectrometry.

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath Analysis
Description: Breath will be analyzed in all three groups using gas chromatography mass spectrometry.
Study: NCT02783378

Intervention type: DRUG
Group type: OTHER
Intervention: Gaviscon Syrup
Study: NCT02646839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMacs TCR alpha-beta-Biotin system
Description: Graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells
Study: NCT00941369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine (HOE901)/NPH Insulin
Description: Arm 1: Subcutaneous injection of Insulin Glargine with the TactiPen® injector pen once daily at any time, but each day at the same time~Arm 2: Subcutaneous injection of Protamine Hagedorn basal insulin with the TactiPen® injector pen once or twice daily at the discretion of the treating physician~The starting dose is 10 I.U. (NPH basal insulin) resp. 10 U (insulin glargine) per day.~The dose adjustments will be based on the results of self-monitoring.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine (HOE901)/NPH Insulin
Description: Arm 1: Subcutaneous injection of Insulin Glargine with the TactiPen® injector pen once daily at any time, but each day at the same time~Arm 2: Subcutaneous injection of Protamine Hagedorn basal insulin with the TactiPen® injector pen once or twice daily at the discretion of the treating physician~The starting dose is 10 I.U. (NPH basal insulin) resp. 10 U (insulin glargine) per day.~The dose adjustments will be based on the results of self-monitoring.
Study: NCT04556032

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Ergothioneine 10 mg/d
Description: L-Ergothioneine 10 mg/d

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Ergothioneine 25 mg/d
Description: L-Ergothioneine 25 mg/d

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg/d L-Ergothioneine
Study: NCT00334360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Dexmedetomidine (delivered by a computer-controlled IV infusion to target a plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
Study: NCT03513302

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nitrate
Description: 2 x 70 mL concentrated beet root juice per day for 14 days.
Study: NCT00334360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buspirone
Description: Buspirone, 60 mg orally, will be given during controlled hypothermia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bus and Dex
Description: the combination of 60 mg buspirone and dexmedetomidine (target plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
Study: NCT03263494

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitor (CGM)
Description: Participants randomized to the CGM Group will receive a Dexcom CGM device and be instructed on how to utilize the CGM data in real time for diabetes management.
Study: NCT00894322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once weekly
Description: subcutaneous injection, 10.0 mg, single injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once weekly
Description: subcutaneous injection, 2.0 mg, once a week for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection, volume equivalent to Cohort 2 experimental intervention, once a week for 12 weeks
Study: NCT03522974

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Strawberry powder
Description: Freeze dried strawberry powder

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Strawberry powder
Description: Freeze dried strawberry powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: 40 g/d placebo powder matched for taste and appearance
Study: NCT04650802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait training
Description: Participants receive five weeks individual robotic gait training in LOPES II, targeting paretic propulsion (60 minutes, two time a week). The robotic gait training is complemented with daily home exercises (15 minutes/day) focusing on increasing strength and practice of learned strategies in daily life.
Study: NCT03194698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light Treatment (IPL)
Description: IPL is a high-intensity light source consisting of visible light in the wavelength range of 515-1200 nm, that is aimed at the eyes. Treatments are spaced four to six weeks apart for a total of 4 treatments.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meibomian Gland Expression
Description: Manual expression of the meibomian glands by placing the thumb against the lid margin and press firmly against the eyeball to determine the percentage of meibomian pores that are blocked. This assessment is performed on both the upper and lower lid of each eye.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Meibomian Gland Expression
Description: Manual expression of the meibomian glands by placing the thumb against the lid margin and press firmly against the eyeball to determine the percentage of meibomian pores that are blocked. This assessment is performed on both the upper and lower lid of each eye.
Study: NCT02484742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insomnia symptom induction
Description: Several nights during the 18-day stay will be disrupted, such that we delay sleep onset, advance sleep off set, and the sleep period will be disrupted by frequent nighttime awakenings.
Study: NCT04946539

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: Enthesitis assessment via ultrasonography
Study: NCT04208594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: comparing between both drugs for the effect of hypotensive anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: comparing between both drugs for the effect of hypotensive anesthesia
Study: NCT03195543

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet function analyzer-100
Description: The PFA-100 system evaluates primary hemostasis in whole blood samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet function analyzer-100
Description: The PFA-100 system evaluates primary hemostasis in whole blood samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Light transmission aggregometry
Description: Light transmission aggregometry is the gold standard method for assessing platelet function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Light transmission aggregometry
Description: Light transmission aggregometry is the gold standard method for assessing platelet function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Rotational thromboelastometry
Description: ROTEM is a viscoelastic method for hemostasis testing in whole blood.This assay investigates the interaction of blood cells, coagulation factors and their inhibitors during clotting and subsequent fibrinolysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Rotational thromboelastometry
Description: ROTEM is a viscoelastic method for hemostasis testing in whole blood.This assay investigates the interaction of blood cells, coagulation factors and their inhibitors during clotting and subsequent fibrinolysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Endogenous thrombin potential
Description: The endogenous thrombin potential assesses the amount of thrombin which can be generated after the in vitro activation of coagulation and represents the balance between pro- and anti-coagulant forces in plasma.

Intervention type: DIAGNOSTIC_TEST
Intervention: Endogenous thrombin potential
Description: The endogenous thrombin potential assesses the amount of thrombin which can be generated after the in vitro activation of coagulation and represents the balance between pro- and anti-coagulant forces in plasma.
Study: NCT03659591

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behaviour Therapy
Description: CBT will be delivered in group format, consisting of 10 weekly two-hour sessions, with 10 participants per group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive Psychological Training
Description: APT will be delivered in group format, consisting of 5 weekly two-hour sessions, with 20 participants per group